Detailed information

The company was featured in the first edition of The 3D Printing World Guide, on pages 12-13. Browse the full offer, history and legacy.

The 3D Printing World Guide: CANADA

Business

Business activities:

Activity

Gallery

Overview

Axolotl Biosciences is a women-led biotech startup founded in Victoria, BC, specializing in the production of high-quality bioinks for 3D bioprinting human tissue models. It’s flagship product, TissuePrint, as well as upcoming bioinks BrainPrint and HeartPrint, are designed to maintain over 90% cell viability. They support the differentiation of sensitive cells post-printing, including stem cells, neurons, and cardiac cells. These bioinks allow for the creation of more accurate human tissue models that can help advance current drug discovery and personalized medicine processes.

Axolotl’ bioinks are xeno-free, easy-to-use, and compatible with multiple bioprinting platforms- increasing accessibility and collaboration across a variety of research settings. Additionally, its products utilize Axolotl’s patented drug-releasing microsphere technology, which supports advanced tissue modeling through controlled cellular differentiation.

Legacy

Axolotl is unique in its approach to bioink development, prioritizing the needs of cells over printability. Unlike conventional bioinks, Axolotl’s products are designed for long-term cell culture development, creating tissue models that closely mimic human physiology. This innovation allows researchers to achieve both accurate printing and biological functionality in their tissue models.

Key achievements include the launch of our flagship product, TissuePrint, in 2022, and the ongoing development of two future bioinks designed for neural and cardiac tissue modeling. Further, the drug-releasing microsphere technology used in our smart bioinks was recently awarded a patent. Axolotl has gained international recognition, winning awards at the Formnext and Falling Walls conferences in Germany, and being named a finalist in the Hello Tomorrow Global Challenge. As the only Canadian and one of two North American companies recognized at these conferences, we are proud to drive innovation in bioprinting.